Your activity: 73 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Anaphylaxis: Emergency treatment

Anaphylaxis: Emergency treatment
Authors:
Ronna L Campbell, MD, PhD
John M Kelso, MD
Section Editors:
Ron M Walls, MD, FRCPC, FAAEM
Adrienne G Randolph, MD, MSc
Deputy Editor:
Anna M Feldweg, MD
Literature review current through: Feb 2022. | This topic last updated: Apr 14, 2021.

INTRODUCTION — Anaphylaxis is a potentially fatal disorder that is under-recognized and undertreated. This may partly be due to failure to appreciate that anaphylaxis is a much broader syndrome than "anaphylactic shock," and the goal of therapy should be early recognition and treatment with epinephrine to prevent progression to life-threatening respiratory and/or cardiovascular symptoms and signs, including shock.

This topic will discuss the treatment of anaphylaxis. The clinical manifestations and diagnosis of anaphylaxis, pathophysiology, and unique features of anaphylaxis in specific patient groups are reviewed separately:

(See "Anaphylaxis: Acute diagnosis".)

(See "Biphasic and protracted anaphylaxis".)

(See "Pathophysiology of anaphylaxis".)

(See "Fatal anaphylaxis".)

(See "Anaphylaxis: Confirming the diagnosis and determining the cause(s)".)

(See "Anaphylaxis in infants".)

(See "Anaphylaxis in pregnant women".)

Recommendations for dosing and prescribing epinephrine for use by patients and caregivers in the community setting are provided separately. (See "Prescribing epinephrine for anaphylaxis self-treatment", section on 'Dosing'.)

IMMEDIATE MANAGEMENT — Prompt assessment and treatment are critical in anaphylaxis, as respiratory or cardiac arrest and death can occur within minutes [1-9]. It is also important to treat anaphylaxis promptly because it appears to be most responsive to treatment in its early phases, based on the observation that delayed epinephrine injection is associated with fatalities [10-15].

The tables provide rapid overviews of the initial assessment and emergency management of anaphylaxis in adults (table 1) and in children (table 2).

The cornerstones of initial management are the following [16-21]:

Removal of the inciting cause, if possible (eg, stop infusion of a suspect medication).

Call for help (summon a resuscitation team in a hospital setting or call 911 or an equivalent emergency medical services number in a community setting).

Intramuscular (IM) injection of epinephrine at the earliest opportunity, followed by additional epinephrine by IM or intravenous (IV) injection as needed.

Placement of the patient in the supine position with the lower extremities elevated, unless there is prominent upper airway swelling prompting the patient to remain upright (and often leaning forward). If the patient is vomiting, placement of the patient semirecumbent with lower extremities elevated may be preferable. Place pregnant patients on their left side.

Supplemental oxygen.

Volume resuscitation with IV fluids.

In a series of 164 fatalities due to anaphylaxis, the median time interval between onset of symptoms and respiratory or cardiac arrest was 5 minutes in iatrogenic anaphylaxis, 15 minutes in stinging insect venom-induced anaphylaxis, and 30 minutes in food-induced anaphylaxis [1]. A more detailed review of fatal anaphylaxis is presented separately. (See "Fatal anaphylaxis".)

Initial assessment and management — A number of critical components in the initial management needs to be instituted concomitantly [22-27]. Rapid overview tables that summarize important interventions in the first few minutes of management are provided for adults (table 1) and for infants and children (table 2):

Attention should focus first on airway, breathing, and circulation, as well as adequacy of mentation. The lips, tongue, and oral pharynx are assessed for angioedema, and the patient is asked to speak his or her name to assess periglottic or glottic swelling. The skin is examined for urticaria or angioedema, which (if present) is helpful in confirming the diagnosis.

Epinephrine should be injected IM into the mid-outer aspect of the thigh (table 1 and table 2) [10,17-21,28,29]. If symptoms are severe, an IV epinephrine infusion should be prepared in case it is needed. (See 'Intramuscular epinephrine injection (preferred)' below.)

If the upper airway is not edematous, the patient should be placed in the recumbent position, with the lower extremities elevated to maximize perfusion of vital organs (and pregnant patients on their left side to minimize compression of the inferior vena cava by the gravid uterus) [30]. The recumbent position also helps prevent severe hypotension, subsequent inadequate cardiac filling, and pulseless cardiac activity. If patients are kept upright or moved to an upright posture in the setting of hypoperfusion, death can occur within seconds (ie, "empty ventricle syndrome") [21]. However, individuals with respiratory distress or vomiting may not tolerate the recumbent position and should be placed in a position of comfort, with lower extremities elevated, if possible. (See "Fatal anaphylaxis".)

Supplemental oxygen, initially using a nonrebreather mask at 15 liters/minute flow rate or commercial high flow oxygen masks (providing at least 70 percent and up to 100 percent oxygen) should be administered.

Two large-bore IV catheters (ideally 14 to 16 gauge for most adults) should be inserted in preparation for rapid administration of fluids and medications. Intraosseous access should be obtained if IV access is not readily obtainable.

In normotensive adults, isotonic (0.9 percent) saline should be infused at a rate of 125 mL/hour to maintain venous access. In normotensive children, isotonic saline should be infused at an appropriate maintenance rate for weight in order to maintain venous access. (See "Maintenance intravenous fluid therapy in children".)

Continuous electronic monitoring of cardiopulmonary status, including frequent measurements of blood pressure (BP), heart rate, and respiratory rate, as well as monitoring of oxygen saturation by pulse oximetry, is required for the duration of the episode.

Airway management — The initial steps in anaphylaxis management involve a rapid assessment of the patient's airway [22-26]:

Intubation should be performed on an emergency basis if stridor or respiratory distress due to upper airway compromise is present.

Preparations for early intubation should be made if there is any airway involvement or significant edema of the tongue, oropharyngeal tissues, including the uvula, or if voice alteration has occurred, especially if only a small amount of time has elapsed since the exposure. Early presence of upper airway edema represents rapidly developing airway compromise, requiring prompt action.

In a minority of cases, an emergency cricothyroidotomy may be required to secure the airway if severe upper airway edema prevents access to the glottic aperture, even with use of a video laryngoscope.

Intubation may be difficult in individuals in whom edema distorts the upper airway anatomical landmarks. Early awake flexible scope intubation or awake intubation using a rigid video laryngoscope with sedation and topical anesthesia/vasoconstriction are the methods of choice, unless intubation occurs early when there is minimal disruption of upper airway anatomy. In this latter case, a "double set-up" rapid sequence intubation, preferably with a video laryngoscope and surgical airway backup, are reasonable alternatives. Failed attempts at intubation can lead to complete airway obstruction and fatality. Therefore, upper airway closure in the setting of anaphylaxis should be managed by the most proficient clinician available. This may require immediate collaboration between an emergency medicine specialist and an anesthesiologist, otolaryngologist, or intensivist with training and experience in the management of the difficult airway, but delay should not occur while seeking consultation. If airway assistance is not immediately available, intubation should ensue. (See "Flexible scope intubation for anesthesia" and "Approach to the anatomically difficult airway in adults outside the operating room" and "The difficult pediatric airway".)

Intravenous fluids — Intravenous (IV) access should be obtained in all cases of anaphylaxis. Massive fluid shifts can occur rapidly due to increased vascular permeability, with transfer of up to 35 percent of the intravascular volume into the extravascular space within minutes [17]. Any patient whose hypotension does not respond promptly and completely to IM epinephrine should receive large volume fluid resuscitation [22-26]. The following principles should guide therapy:

Fluid resuscitation should be initiated immediately in patients who present with orthostasis, hypotension, or incomplete response to IM epinephrine.

Adults should receive 1 to 2 liters of normal saline at the most rapid flow rate possible in the first minutes of treatment. Large volumes of fluid (eg, up to 7 liters) may be required.

Children should receive normal saline in boluses of 20 mL/kg, each over 5 to 10 minutes, and repeated, as needed. Large volumes of fluid (up to 100 mL/kg) may be required [31].

Normal saline is preferred over other solutions in most situations because other solutions have potential disadvantages:

Lactated Ringer (LR) solution can potentially contribute to metabolic alkalosis, although large volumes of normal saline can cause hyperchloremic metabolic acidosis, so some clinicians change from normal saline to LR if very large volumes are proving necessary.

Dextrose is rapidly extravasated from the circulation into the interstitial tissues.

Colloid solutions (eg, albumin or hydroxyethyl starch) confer no survival advantage in patients with distributive shock and are more costly [32].

Patients should be monitored carefully and continuously for clinical response and for volume overload. (See "Treatment of severe hypovolemia or hypovolemic shock in adults" and "Hypovolemic shock in children: Initial evaluation and management".)

Pregnant women: Additional considerations — Additional precautions and considerations are important in the management of anaphylaxis in pregnant women. For example, during labor and delivery, positioning of the patient on her left side, providing high flow supplemental oxygen, and maintaining a systolic BP of at least 90 mmHg, as well as continuous fetal monitoring, are critically important [23]. (See "Anaphylaxis in pregnant women", section on 'Management'.)

PHARMACOLOGIC TREATMENTS

Rapid overview — The tables provide rapid overviews of the emergency management of anaphylaxis in adults (table 1) and children (table 2). The treatment recommendations in this section are consistent with available practice parameters [22,23,25-27,33]. Each pharmacologic therapy is discussed further below.

Anaphylaxis is variable and unpredictable. It may be mild and resolve spontaneously due to endogenous production of compensatory mediators or it may be severe and progress within minutes to respiratory or cardiovascular compromise and death [34]. At the onset of an anaphylactic episode, it is not possible to predict how severe it will become, how rapidly it will progress, and whether it will resolve promptly and completely or not, because the factors that determine the course of anaphylaxis in an individual patient are not fully understood. Because of these variables, it is important to administer intramuscular (IM) epinephrine early to prevent the possible progression to life-threatening manifestations.

Epinephrine — Epinephrine is the first and most important treatment for anaphylaxis, and it should be administered as soon as anaphylaxis is recognized to prevent the progression to life-threatening symptoms as described in the rapid overviews of the emergency management of anaphylaxis in adults (table 1) and children (table 2). Delayed epinephrine injection is associated with fatalities [10-15]. Epinephrine should also be administered to patients who have symptoms or signs consistent with impending anaphylaxis when the clinical suspicion for anaphylaxis is high, even if formal diagnostic criteria are not met.

Dosing and administration — Epinephrine is commercially available in different concentrations. Great care must be taken to use the correct dilution in order to avoid inducing cardiac complications [22-26]. Confusion persists among clinicians regarding the optimal epinephrine dose and route of administration for the initial treatment of anaphylaxis [35,36].

Intramuscular epinephrine injection (preferred) — Intramuscular (IM) injection is the preferred route for initial administration of epinephrine for anaphylaxis in most settings and in patients of all ages (table 3) [37,38]. IM injection is recommended over subcutaneous injection because it consistently provides a more rapid increase in the plasma and tissue concentrations of epinephrine [19,20]. IM injection is also preferred over intravenous (IV) bolus because it is faster in many situations and safer (ie, lower risk of cardiovascular complications, such as severe hypertension and ventricular arrhythmias).

The epinephrine dilution for IM injection contains 1 mg/mL. Ampules of 1 mg/mL were previously labeled as 1:1000, but to help prevent medication errors, ratio expressions were removed from epinephrine labels in the United States in 2016 [39]. Only the amount per mL will be listed [40]. Ratio labeling remains in place in some other countries.

IM dosing – For situations where an exact dose can be drawn up and administered, the recommended dose of epinephrine for patients of any age is 0.01 mg/kg (maximum dose of 0.5 mg) per single dose, injected IM into the mid-outer thigh (vastus lateralis muscle). The dose should be drawn up using a 1 mL syringe using the 1 mg/mL formulation of epinephrine.

In health care settings, where use of an autoinjector is preferred or estimating the dose helps to avoid delays, the following approach may be used (table 3):

Infants weighing <10 kg should be given an exact weight-based dose (not estimated), whenever possible. However, if drawing up an exact dose is likely to cause a significant delay in a patient with severe symptoms or who is rapidly deteriorating, the 0.1 mg dose can be given by autoinjector or by drawing up 0.1 mL of the 1 mg/mL solution. If the 0.1 mg autoinjector is not available, the 0.15 mg autoinjector can be used. It is expected that the side effects of epinephrine would be mild and transient at the plasma concentrations achieved [41].

Infants and children weighing from 10 kg to 25 kg can be given 0.15 mg by autoinjector or by drawing up 0.15 mL of the 1 mg/mL solution. We prefer use of the autoinjector in these patients for speed, reliability, and ease of use [42].

Patients weighing >25 to 50 kg can be given 0.3 mg by autoinjector or by drawing up 0.3 mL of the 1 mg/mL solution. We prefer use of the autoinjector in these patients for speed, reliability, and ease of use [42].

Patients who weigh >50 kg can be given 0.5 mg (0.5 mL of the 1 mg/mL solution). If the patient is obese, this can be administered using a 1.5-inch needle to penetrate the subcutaneous fat. However, if drawing up an exact dose is likely to cause a significant delay in a rapidly deteriorating patient, the 0.3 mg dose can be given by autoinjector.

The needle used in adults and children should be long enough to penetrate the subcutaneous adipose tissue over the vastus lateralis muscle. Realistically, however, IM injection into the thigh may be impossible in some patients, especially those who are overweight or obese [43,44]. Although the best approach in this situation has not been studied, we suggest as deep an injection as possible into the muscle.

Assessing response to IM epinephrine – Most patients respond to a single dose of IM epinephrine, particularly if it is given promptly after the onset of symptoms. However, when epinephrine is administered in an out-of-hospital area, emergency response (911 service or the equivalent) should be activated, and the patient should be taken to a hospital for further evaluation. IM epinephrine may be repeated at 5- to 15-minute intervals if there is no response or an inadequate response or even sooner if clinically indicated [10,18,23-25,27,45,46]. When additional IM doses are required, typically one or rarely two additional doses are needed (eg, in patients with severe anaphylaxis and those who cannot access emergency care promptly) [47,48]. Retrospective studies indicate that a second dose is necessary in 12 to 36 percent of cases [49-55]. Patients with a history of previous anaphylaxis and those presenting with flushing, diaphoresis, or dyspnea were more likely to require multiple doses of epinephrine to control symptoms in an observational study [56].

In patients who continue to be hypotensive after initial IM epinephrine, IV fluids should be administered. It is also prudent to begin preparing an epinephrine solution for slow, continuous infusion early, so that it is ready in case the patient fails to respond to repeated IM epinephrine and IV fluids. (See 'Intravenous fluids' above and 'Intravenous epinephrine continuous infusion and indications' below.)

Intravenous epinephrine by slow bolus (avoid or use only with caution) — IV bolus epinephrine is associated with significantly more dosing errors and cardiovascular complications than IM epinephrine and should be avoided when possible [10,14,35,37,38]. Slow, continuous infusion is preferred if patients have not responded to IM injections [24,57]. In an observational study of 362 doses of epinephrine administered to 301 patients for the emergency management of anaphylaxis, there were four overdoses, all of which occurred with IV bolus administration [37]. Adverse cardiovascular events were significantly more likely with IV bolus compared with IM administration (3 of 30 versus 4 of 316, respectively).

Nonetheless, there may be situations in which a slow IV bolus of epinephrine is indicated, such as when a patient is suffering cardiovascular collapse or impending cardiovascular collapse that is refractory to IM epinephrine and volume resuscitation, and an epinephrine infusion is not available.

In such cases in an adult or adolescent, this is accomplished by the slow administration of a 50 to 100 mcg (0.05 to 0.1 mg) IV bolus of epinephrine, ideally with hemodynamic monitoring. This is best administered by slow push of 0.5 to 1 mL of 0.1 mg/mL epinephrine solution ("cardiac" epinephrine, available in 10 mL prefilled syringes, containing 1 mg of epinephrine, and stocked on resuscitation carts). Note that for anaphylaxis, the dose is 1/10th or less of the IV epinephrine dose used in cardiac arrest (advanced cardiac life support). The administration of 0.5 to 1 mL (ie, maximum 1/10th of the total syringe volume) provides a dose of 50 to 100 mcg and is given over one to 10 minutes, followed by at least three minutes of observation before considering repeat dosing. Usually, a response is observed after a single dose, providing sufficient time to prepare an infusion. If the patient remains severely hypotensive or has shown little response in either heart rate or blood pressure (BP) to the first dose, a second dose is administered in the same way. As soon as infusion is available, bolus injection is discontinued and replaced by titration of the solution [27,58,59]. Note that the "cardiac" epinephrine solution was previously labeled 1:10,000, although this practice was discontinued in 2016 in the United States [39]. Ratio labeling remains in place in some other countries.

We avoid the use of IV epinephrine boluses in infants and children because data are sparse on the efficacy of safety of this approach and dosing is not well-established. Children who are not responding to initial IM epinephrine and fluid resuscitation should be treated with an IV infusion of epinephrine.

Intravenous epinephrine continuous infusion and indications — Patients who do not respond to several IM injections of epinephrine and aggressive fluid resuscitation may not be adequately perfusing muscle tissues, as most commonly occurs in individuals presenting with profound hypotension or symptoms and signs suggestive of impending shock (dizziness, incontinence of urine and/or stool).

Such patients should receive epinephrine by IV infusion, with the rate titrated according to response and the presence of continuous electronic hemodynamic monitoring. IV infusions of epinephrine should preferably be given by clinicians who are trained and experienced in the administration of vasopressors and can titrate the rate of infusion (and therefore the epinephrine dose) using continuous noninvasive monitoring of BP, heart rate, and function.

Preparing infusion solutionsEpinephrine is commercially available in several dilutions. Great care must be taken to use the correct dilution in order to avoid overdosing the patient [35]. To prepare an epinephrine IV maintenance infusion, the commercially available epinephrine solution (eg, ampule, syringe) must be further diluted. To reduce the risk of making a medication error, we suggest that centers have a protocol available that includes steps on how to prepare and administer an epinephrine infusion.

A simple method for quickly preparing a solution of 1 mcg/mL for adults and adolescents is to add the entire 10 mL contents of a 0.1 mg/mL prefilled "cardiac" epinephrine syringe (a total of 1 mg) to a 1000 mL (1 liter) bag of normal saline. The resultant solution of 1 mcg/mL delivers 1 mcg/minute of epinephrine for each 60 mL/hour of solution infused. Therefore, 120 mL/hour will deliver 2 mcg/minute and so forth (table 4).

For adolescent/adult patients who have already received large quantities of IV fluids (4 or more liters), a more concentrated solution (4 mcg/mL) is preferable. Using a more concentrated solution allows titration of epinephrine infusion and administration of bolus crystalloid solution to be done independent of one another. To prepare a 4 mcg/mL solution, add the entire 10 mL contents of one 0.1 mg/mL epinephrine syringe to a 250 mL bag of normal saline. The resultant solution delivers 1 mcg/minute of epinephrine for each 15 mL/hour of infusion. Therefore, 30 mL/hour delivers 2 mcg/minute, 45 mL/hour delivers 3 mcg/minute, and so forth (table 5).

For infants and children, a more concentrated solution of 10 mcg/mL is more appropriate to avoid excessively large infusion volumes.

Initial infusion rates:

Adults – Start the IV epinephrine infusion at 0.1 mcg/kg/minute (range: 0.05 to 0.2 mcg/kg/minute) and increase it every two to three minutes by 0.05 mcg/kg/minute until BP and perfusion improve. The maximum dose is not known and will be different for every patient, but rarely will a patient require a dose exceeding 1 mcg/kg/minute. In monitored patients with impending cardiovascular collapse or progression to shock, a higher initial dose of 0.2 mcg/kg/minute and more rapid titration may be warranted.

As an example, for an 80 kg patient, the starting dose is 8 mcg/minute (calculation: 80 kg x 0.1 mcg/kg/minute). Using the dilute (1 mcg/mL) solution, the infusion pump is set to deliver 8 mL/minute (480 mL/hour) (table 4). Or if using the more concentrated 4 mcg/mL solution the infusion pump is set to initially deliver 2 mL/minute (120 mL/hour) (table 5).  

The infusion rate is increased by one-half of the starting rate every few minutes (in this example, increase infusion by 4 mL/minute (240 mL/hour) if using the dilute 1 mcg/mL solution or by 1 mL/minute (60 mL/hour) if using the more concentrated 4 mcg/mL solution). The dose is titrated to effect on BP with continuous noninvasive monitoring. When BP increases by 10 to 15 percent, the infusion rate is held at that level for three to five minutes to see if improvement continues, and the infusion rate is then adjusted accordingly [22]. If there is a risk of volume overload, the more dilute solution should only be used as a temporizing measure until a more concentrated solution is available. To reduce the risk of making a medication error, we suggest that centers have a protocol available that includes steps on how to prepare and administer epinephrine infusion.

Infants and children – The dose for IV infusion of epinephrine is 0.1 to 1 mcg/kg/minute with use of an infusion pump, titrated to effect on BP with continuous cardiac monitoring and frequent noninvasive BP monitoring. To reduce the risk of making a medication error, we suggest that centers have a protocol available that includes steps on how to prepare and administer epinephrine infusion. Examples of pediatric infusions are provided (table 6 and table 7).

Epinephrine administration via central line is preferred, although central line insertion should not delay the initiation of IV epinephrine infusion [60,61]. When a patient does not have a central venous catheter, epinephrine can be temporarily administered through an appropriately positioned, large-bore, peripheral venous catheter until a central venous catheter is inserted. Closely monitor the catheter site throughout the infusion to avoid extravasation injury.

Epinephrine mechanisms of action — The pharmacologic actions of epinephrine address the pathophysiologic changes that occur in anaphylaxis better than any other medication. It decreases mediator release from mast cells [62], prevents or reverses obstruction to airflow in the upper and lower respiratory tracts, and prevents or reverses cardiovascular collapse (table 1 and table 2).

The therapeutic actions of epinephrine include the following (table 8) [10,12-15,18,45]:

Alpha-1-adrenergic agonist effects – Increased vasoconstriction, increased peripheral vascular resistance, and decreased mucosal edema (eg, in the upper airway).

Beta-1-adrenergic agonist effects – Increased inotropy and increased chronotropy.

Beta-2-adrenergic agonist effects – Increased bronchodilation and decreased release of mediators of inflammation from mast cells and basophils.

Adverse effects — In patients of all ages, epinephrine administered in therapeutic doses by any route often causes mild transient pharmacologic effects, such as anxiety, restlessness, headache, dizziness, palpitations, pallor, and tremor [14,15,18,45]. These symptoms and signs are similar to those occurring during the physiologic "fight or flight" response due to endogenous epinephrine that occurs normally in sudden frightening or life-threatening situations.

Rarely, epinephrine may lead to ventricular arrhythmias, angina, myocardial infarction, pulmonary edema, sudden sharp increase in BP, and intracranial hemorrhage. However, anaphylaxis itself can lead to angina, myocardial infarction, and cardiac arrhythmias in the absence of any exogenous epinephrine or before exogenous epinephrine is administered [63].

Serious adverse effects occur most commonly after an IV bolus injection, particularly if an inappropriately large dose is administered [10,14,35,37]. (See 'Situations requiring caution' below.)

Situations requiring caution — There are no absolute contraindications to epinephrine use in anaphylaxis [10,12-15,22-26,45]. The risk of death or serious neurologic sequelae from hypoxic-ischemic encephalopathy due to inadequately treated anaphylaxis usually outweighs other concerns [10,12-15,22-26,45]. Existing evidence clearly favors the benefit of epinephrine administration in anaphylaxis. However, formal risk-benefit analyses are not possible, and sound clinical judgment is essential.

Subgroups of patients might theoretically be at higher risk for adverse effects during epinephrine therapy:

Patients with cardiovascular diseases. The small number of studies examining epinephrine use in older adults with anaphylaxis suggests that while intravenous epinephrine is associated with more adverse cardiovascular effects, intramuscular injection is well-tolerated [37,38]. Reluctance to administer epinephrine due to fear of adverse cardiac effects should be countered by the awareness that the heart is a target organ in anaphylaxis. In the healthy human heart, mast cells are present throughout the myocardium and in the intima of coronary arteries. In patients with coronary artery disease, mast cells are found in atherosclerotic lesions and contribute to atherogenesis. Anaphylaxis can unmask subclinical coronary artery disease, and myocardial infarction and/or arrhythmias can occur during anaphylaxis, even if epinephrine is not injected [64,65]. Moreover, anaphylaxis itself can cause vasospasm, arrhythmias, and myocardial infarction in patients, including children, with healthy hearts as confirmed by normal electrocardiograms, echocardiograms, and coronary angiograms after resolution of anaphylaxis [66].

Patients receiving monoamine oxidase inhibitors (which block epinephrine metabolism) or tricyclic antidepressants (which prolong epinephrine duration of action).

Patients with certain pre-existing conditions, such as recent intracranial surgery, aortic aneurysm, uncontrolled hyperthyroidism or hypertension, or other conditions that might place them at higher risk for adverse effects related to epinephrine.

Patients receiving stimulant medications (eg, amphetamines or methylphenidate used in the treatment of attention deficit hyperactivity disorder) or abusing cocaine that might place them at higher risk for adverse effects from epinephrine.

Efficacy — Epinephrine is the best studied medication in anaphylaxis, although randomized, placebo-controlled trials of epinephrine in humans experiencing anaphylaxis have never been performed for ethical reasons. The evidence for its use comes from observational studies, randomized-controlled clinical pharmacology studies in patients not experiencing anaphylaxis, studies of anaphylaxis in animal models, and epidemiologic studies, including fatality studies. Several case series have implicated the failure to administer epinephrine early in the course of treatment as a consistent finding in anaphylaxis deaths [1-7,67].

In a series of 13 fatal and near-fatal food-induced anaphylactic reactions in children and adolescents, the six patients who died had symptom-onset within one to five minutes after ingestion of the culprit food but did not receive their first dose of epinephrine until 25, 60, 80, 90, 125, and 180 minutes after the food was ingested. The authors concluded that the failure to recognize severity of the reactions and to administer epinephrine promptly increased the risk of a fatal outcome [2].

In a series of anaphylactic deaths occurring from 1992 to 1998, only 20 percent of 24 patients were given epinephrine at any point in their treatment [3].

In the fatality series described previously, only 14 percent of the 164 patients dying from anaphylaxis received epinephrine before respiratory or cardiac arrest, although 62 percent of the 164 patients eventually received it before demise [1].

In addition, anaphylaxis occurring during evaluation of venom immunotherapy has been investigated prospectively. In one study, 68 patients with a history of anaphylaxis to insect stings were randomly assigned to venom immunotherapy or placebo immunotherapy [17]. Following this, all were stung in a controlled, monitored setting and treated (if needed) with a standardized protocol of high-flow oxygen, epinephrine infusion, and normal saline rapid infusion. Nineteen of the 21 patients in the placebo group developed anaphylaxis and received epinephrine. Symptoms responded within five minutes in all but one patient. In nine patients, an initial attempt to stop the epinephrine infusion was followed by a return of symptoms, which subsided again once the epinephrine infusion was restarted.

In a retrospective chart review of 234 children who received epinephrine for food-induced anaphylaxis, treatment with epinephrine prior to arrival to the emergency department was associated with a significantly lower risk of hospitalization [68]. Although the time between food exposure and administration of epinephrine could not be precisely determined, children who received epinephrine earlier (often because they had an epinephrine autoinjector) were released from the emergency department sooner and were less likely to require hospital admission compared with those who received it only after arrival (17 versus 43 percent).

Finally, there is extensive clinical experience among allergy practitioners with giving epinephrine to treat anaphylaxis occurring in response to immunotherapy. This is a unique situation because allergy clinic staff observe patients closely for the symptoms and signs of anaphylaxis and reactions are detected at very early stages. Over the past few decades, consensus has been reached that even mild systemic reactions are best treated immediately with epinephrine, as this appears to prevent progression to more severe symptoms more effectively than any other available therapies. At the time the autoinjector is used or epinephrine is administered in another form, 911 response should be initiated, with the clear complaint of "anaphylaxis," without waiting to see if the reaction worsens. The 911 call can always be aborted if the patient recovers or the patient can be assessed by paramedics and not transported. As a result, successive guidelines for treatment of immunotherapy reactions have called for epinephrine to be given as soon as a systemic reaction of any severity is detected [69]. In studies in which all or most patients who developed anaphylaxis after allergen immunotherapy were treated promptly with epinephrine injections, symptoms were mild, and no additional injections of epinephrine were given, even in the 10 to 23 percent of reactions that were biphasic [70].

Glucagon for patients taking beta-blockers — Beta-blocker therapy, alone or in combination with angiotensin-converting enzyme inhibitors, has been associated with more severe anaphylaxis [71]. However, in a retrospective study of 789 patients presenting to the emergency department, patients taking beta-blockers were no more likely to need epinephrine or to need additional doses of epinephrine than patients not taking beta-blockers, so the clinical impact may be relatively small [72]. Nonetheless, although epinephrine should still be used at first-line therapy, even in patients taking beta-blockers, if a patient taking beta-blockers appears to be refractory to epinephrine, glucagon can be administered because it has inotropic and chronotropic effects that are not mediated through beta-receptors [73,74].

Adult dosing is 1 to 5 mg slow IV bolus over five minutes. May be followed by an infusion of 5 to 15 mcg/minute titrated to effect.

Pediatric dosing is 20 to 30 mcg/kg (maximum 1 mg) slow IV bolus over five minutes. May be followed by an infusion of 5 to 15 mcg/minute titrated to effect (ie, not weight-based).

Rapid administration of glucagon can induce vomiting. Therefore, protection of the airway, for example, by placement in the lateral recumbent position, is important in drowsy or obtunded patients.

Adjunctive agents — Agents that may be given as adjunctive therapies to epinephrine in the treatment of anaphylaxis include H1 antihistamines, H2 antihistamines, bronchodilators, and glucocorticoids. None of these medications should be used as initial treatment or as sole treatment, because they do not relieve upper or lower respiratory tract obstruction, hypotension, or shock and are not lifesaving.

H1 antihistamines — Epinephrine is first-line treatment for anaphylaxis, and there is no known equivalent substitute. H1 antihistamines (such as diphenhydramine or cetirizine) relieve itch and hives. These medications do not relieve upper or lower airway obstruction, hypotension or shock, and in standard doses, do not inhibit mediator release from mast cells and basophils. A systematic review of the literature failed to retrieve any randomized-controlled trials that support the use of H1 antihistamines in anaphylaxis [11]. While augmenting epinephrine with an H1 antihistamine is reasonable from a symptom control standpoint, antihistamines should only be administered for anaphylaxis after epinephrine has been given.

Second-generation H1 antihistamines (eg, cetirizine) have the advantage of being less sedating than first-generation agents (eg, diphenhydramine, hydroxyzine) [11,15,75]. Cetirizine is available in both IV and oral formulations, while other nonsedating antihistamines (eg, levocetirizine, loratadine, desloratadine, fexofenadine) are only available in oral forms. For anaphylaxis, the IV route is preferred initially. If IV access is not yet established and the patient is conscious and not at risk for aspiration, oral administration can be considered.

Examples of commonly used H1 antihistamines include the following:  

Cetirizine — For adults and children ≥12 years of age, cetirizine 10 mg can be administered IV over 1 to 2 minutes. The duration of action approaches 24 hours.

Children 6 to 11 years of age can receive 5 or 10 mg IV. Children aged 6 months to 5 years can receive 2.5 mg IV.

Diphenhydramine — For adults and children ≥12 years of age, diphenhydramine 25 to 50 mg can be administered IV over 5 minutes, which may be repeated every 4 to 6 hours if necessary up to a maximum daily dose of 400 mg per 24 hours. Excessively rapid IV administration may increase hypotension [76]. Diphenhydramine may cause significant sedation.

For children weighing less than 50 kg, diphenhydramine 1 mg/kg (maximum 50 mg) can be administered IV over 5 minutes, which may be repeated up to a maximum daily dose of 5 mg/kg or 200 mg per 24 hours.

H2 antihistamines — An H2 antihistamine (eg, famotidine) given with an H1 antihistamine may provide some additional relief of hives [77].

Although H2 antihistamines are sometimes administered in anaphylaxis treatment, H2 antihistamines do not relieve upper or lower airway obstruction or shock. Systematic reviews have not identified any randomized-controlled trials that support the use of these agents in anaphylaxis or urticaria [78,79].

If used, famotidine (20 mg in adults, 0.25 mg/kg in children to a maximum of 20 mg/dose) may be infused IV over at least two minutes.

Bronchodilators — For the treatment of bronchospasm not responsive to epinephrine, inhaled bronchodilators (eg, albuterol, salbutamol) should be administered by mouthpiece (or facemask for those whose age or condition requires) and nebulizer/compressor, as needed. Patients with milder respiratory symptoms can receive albuterol by metered-dose inhaler. Bronchodilators are adjunctive treatment to epinephrine because they do not prevent or relieve mucosal edema in the upper airway or shock, for which the alpha-1-adrenergic effects of epinephrine are required [22-26]. The evidence for the use of beta-2-adrenergic agonists in anaphylaxis is extrapolated from their use in acute asthma.

Glucocorticoids — Glucocorticoids are commonly given in the treatment of anaphylaxis; however, there is little evidence of benefit. The onset of action of glucocorticoids takes several hours. Therefore, these medications do not relieve the initial symptoms and signs of anaphylaxis. One rationale for giving them, theoretically, is to prevent the biphasic or protracted reactions that occur in some cases of anaphylaxis. However, a 2020 systematic review failed to find evidence for this effect [80]. (See "Biphasic and protracted anaphylaxis", section on 'Prevention'.)

In the absence of conclusive data or consensus, our approach is not to administer glucocorticoids routinely to patients who respond well to epinephrine and other measures and in whom discharge is anticipated. On the other hand, glucocorticoids may well be beneficial for patients with severe symptoms requiring hospitalization or for those with known asthma and significant bronchospasm that persists after other anaphylaxis symptoms and signs have abated, and we do generally administer them in such situations.

If given, a dose of methylprednisolone of 1 to 2 mg/kg/day for one to two days is sufficient. Glucocorticoids can be stopped after that without a taper. (See "Anaphylaxis: Acute diagnosis", section on 'Time course'.)

REFRACTORY ANAPHYLAXIS — For patients who are not responding to initial measures, admission to an intensive care unit should occur without delay. There are no published prospective studies on the optimal management of refractory anaphylaxis. A retrospective review of 11,596 cases of anaphylaxis identified 42 episodes of refractory anaphylaxis, defined as a lack of response to the equivalent of two or more doses of epinephrine from an autoinjector [81]. One-half of cases were caused by medications and these occurred mostly in the perioperative setting with intravenously-administered drugs. Mortality was 26 percent, compared to less than one percent in patients with severe but treatment-responsive anaphylaxis. None of the patients the series received the agents discussed in this section.

Anaphylactic shock displays features of both distributive (vasodilatory) and hypovolemic shock. The management of severe forms of these types of shock is discussed separately. (See "Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis" and "Hypovolemic shock in children: Initial evaluation and management" and "Evaluation and management of suspected sepsis and septic shock in adults", section on 'Vasopressors' and "Treatment of severe hypovolemia or hypovolemic shock in adults".)

Other vasopressors — The addition of another vasopressor should be considered if the patient continues to be hypotensive despite maximal epinephrine and fluid therapy. It is unclear if the addition of other pressors is superior to epinephrine alone, but one theory about the pathogenesis of refractory anaphylaxis proposes that the clinical manifestations may become refractory to further catecholamine administration, perhaps due to saturation or desensitization of adrenergic receptors [82]. The use of nonadrenergic vasopressors, such as vasopressin, in the management of anaphylaxis refractory to intravenous (IV) epinephrine in adults is discussed elsewhere. Other adrenergic vasopressors can also be considered, such as norepinephrine and dopamine. An emergency medicine practice parameter states, "Norepinephrine, vasopressin, and other pressors have been used with success in patients in anaphylaxis with refractory hypotension" [27]. (See "Use of vasopressors and inotropes", section on 'Vasopressin and analogs'.)

Methylene blue — Vasoplegia (profound vasodilation) may be present in some cases of refractory anaphylaxis. A few case reports and other publications support the use of methylene blue, an inhibitor of nitric oxide synthase and guanylate cyclase, in severe anaphylaxis, mostly in perioperative settings [83-86]. The efficacy and ideal dose of methylene blue is unknown, but a single bolus of 1 to 2 mg/kg given over 20 to 60 minutes has been used in cardiac surgery. Improvement of vasoplegia (eg, increased systemic vascular resistance, reduced vasopressor dose) has been observed within one to two hours in the setting of cardiac surgery, but few data are available about anaphylaxis. This drug should not be given to patients with pulmonary hypertension, underlying glucose-6-phosphate dehydrogenase deficiency, or acute lung injury. We also advise caution regarding potential drug interactions with serotonergic agents. Methylene blue and other vital dyes are also rarely the cause of perioperative anaphylaxis. (See "Postoperative complications among patients undergoing cardiac surgery", section on 'Vasodilatory shock'.)

Extracorporeal membrane oxygenation — Patients suffering from refractory anaphylaxis have been resuscitated with extracorporeal membrane oxygenation (ECMO) or operative cardiopulmonary bypass [87,88]. ECMO is becoming increasingly available in emergency departments and should be considered in patients unresponsive to complete resuscitative efforts in institutions with experience in this technology. The decision to initiate ECMO should be considered early in patients unresponsive to traditional resuscitative measures, before irreversible ischemic acidosis develops. (See "Extracorporeal membrane oxygenation (ECMO) in adults".)

TREATMENT ERRORS — Important errors in the treatment of anaphylaxis include failure to administer epinephrine promptly and delay in epinephrine injection due to over-reliance on antihistamines, albuterol (salbutamol), and glucocorticoids. (See 'Adjunctive agents' above.)

Epinephrine should be administered as soon as possible once anaphylaxis is recognized or if impending anaphylaxis is suspected, even if patients do not meet diagnostic criteria. Delayed administration has been implicated in contributing to fatalities [1-7,67]. A study of 13 fatal or near-fatal, food-induced anaphylactic reactions in children reported that six of the seven children who survived received epinephrine within 30 minutes of ingesting the allergen, whereas only two of the six children who died received epinephrine within the first hour [2].

H1 antihistamines are useful for relieving itching and urticaria. They do not relieve stridor, shortness of breath, wheezing, gastrointestinal symptoms and signs, hypotension, or shock and should not be substituted for epinephrine [11,22,23,26,75].

Bronchodilator treatment with nebulized albuterol (salbutamol) should be given in individuals with severe bronchospasm as an adjunctive treatment to epinephrine. However, albuterol does not prevent or relieve upper airway edema, hypotension, or shock and should not be substituted for epinephrine in the treatment of anaphylaxis.

OBSERVATION AND ADMISSION — All patients with anaphylaxis should be observed until symptoms have completely resolved. There is no consensus regarding the optimal observation period for a patient who has been successfully treated for anaphylaxis in a health care facility [47,80,89-96]. The major concern about premature discharge is that a biphasic reaction may occur, although available evidence suggests that this develops in only approximately 5 percent of patients [91,96-98]. Risk factors for biphasic reactions are not known with certainty, but a meta-analysis found that patients with a severe initial presentation (such as hypotension) or the need for more than one dose of epinephrine may be at increased risk for recurrent symptoms [80]. Biphasic anaphylaxis is discussed in more detail separately. (See "Biphasic and protracted anaphylaxis", section on 'Biphasic anaphylaxis'.)

We suggest the following:

All patients with severe anaphylaxis should be admitted to an observation unit or hospital.

We suggest admission or observation for patients who do not respond promptly to intramuscular epinephrine, require more than one dose of epinephrine, or received epinephrine only after a significant delay (>60 minutes), as these features may be risk factors for a biphasic response [80].

For patients who are not admitted, observation periods can be customized based on reaction severity and patient access to emergency medical care. Further, we suggest that all patients be dismissed with an epinephrine autoinjector whenever possible. One study of a clinical care pathway found that four hours of observation is safe in selected populations (ie, children treated for anaphylaxis without complications and discharged with an epinephrine autoinjector in hand) [99].

Discharge care — All patients who have experienced anaphylaxis should be sent home with the following:

An anaphylaxis emergency action plan

At least one epinephrine autoinjector in hand or a prescription for two epinephrine autoinjectors

Printed information about anaphylaxis and its treatment

(Documented) advice to follow up to an allergist, with a referral if possible

Anaphylaxis emergency action plan — Before discharge, patients should be given a written, personalized anaphylaxis emergency action plan that lists the common symptoms and signs of anaphylaxis and contains information about prompt recognition of anaphylaxis and self-injection of epinephrine.

Action plan forms are available in English and Spanish from Food Allergy Research and Education (Food Allergy & Anaphylaxis Emergency Care Plan) and the American Academy of Pediatrics (Allergy and Anaphylaxis Emergency Plan English, Spanish). These plans are appropriate for patients with anaphylaxis from any cause.

Action plans specific to children are also available (form 1).

Epinephrine autoinjector — Patients should be instructed in how to use an epinephrine autoinjector correctly and provided with an autoinjector. If this not possible, patients should receive a prescription for an autoinjector and advised to fill the prescription immediately. Ideally, two epinephrine autoinjectors should be prescribed because up to 20 percent of patients require more than one dose of epinephrine for the treatment of their anaphylactic reaction [51,52,56]. Recommendations for dosing and prescribing epinephrine for use by patients and caregivers in the community setting are provided separately. (See "Prescribing epinephrine for anaphylaxis self-treatment", section on 'Dosing'.)

Instructions in the proper use of epinephrine autoinjectors should be reviewed verbally, and patients should be given written material or directed to a manufacturer's website providing relevant information. Patient information that can be printed or accessed online is provided. These steps prior to discharge are often overlooked. In a survey of 1885 patients who survived anaphylaxis, 28 percent of those who did not self-administer epinephrine reported that they had never received a prescription for an autoinjector [100]. (See 'Information for patients' below.)

FOLLOW-UP CARE — To reduce the risk of recurrence, patients who have been successfully treated for anaphylaxis subsequently require confirmation of the anaphylaxis cause as well as anaphylaxis education. In a study of emergency department patients with suspected anaphylaxis who followed up with an allergist/immunologist, 35 percent of patients had an alteration in the diagnosis or suspected cause, underscoring the importance of follow-up evaluation [101]. (See "Anaphylaxis: Confirming the diagnosis and determining the cause(s)" and "Long-term management of patients with anaphylaxis".)

Counseling and referral to an allergist — The mnemonic "SAFE" was developed to remind clinicians of the four basic action steps suggested for patients with anaphylaxis who have been treated and are subsequently leaving the emergency department or hospital [102,103]. These steps are: Seek support, Allergen identification and avoidance, Follow-up for specialty care, and Epinephrine for emergencies. The SAFE counseling is outlined below and has been incorporated into printable patient education materials. (See 'Information for patients' below.)

Seek support – Advise the patient that:

He/she has experienced anaphylaxis or "killer allergy," which is a life-threatening condition.

Symptoms of the current episode may recur (without further exposure to the causal agent) up to three days after the initial onset of symptoms.

He/she should self-inject epinephrine and call emergency medical services or get to the nearest emergency facility at the first sign of recurrence of symptoms.

He/she is at risk for repeat episodes of anaphylaxis in the future.

He/she should learn about anaphylaxis (refer the patient to resources). (See 'Information for patients' below.)

Allergen identification and avoidance

Emphasize the importance of avoiding the suspected cause [101]. If the cause is unclear, which is not unusual, it is especially important to refer the patient to an allergist for further evaluation.

Follow-up for specialty care

Advise the patient to follow-up with his or her primary care clinician and obtain a referral to an allergist (or to seek consultation directly with an allergist) for testing to confirm the cause and for ongoing management. Specifically, the suspected cause for the anaphylactic episode should be verified. In one study of over 500 patients with anaphylaxis, evaluation by an allergist/immunologist resulted in an alteration to the diagnosis or suspected cause in more than one-third [101]. The evaluation of a patient following anaphylaxis is reviewed separately. (See "Anaphylaxis: Confirming the diagnosis and determining the cause(s)".)

For anaphylaxis caused by stinging insects, a course of immunotherapy can dramatically reduce the risk of a recurrent reaction. (See "Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action".)

Comorbidities, such as asthma, other chronic pulmonary disease, and cardiovascular disease, should be optimally controlled, as these can increase the risk of fatal anaphylaxis. (See "Fatal anaphylaxis".)

Epinephrine for emergencies

Provide the patient with a prescription for two epinephrine autoinjectors and demonstrate proper use. In addition, give the patient written information about how to recognize anaphylaxis and how to use an epinephrine autoinjector and provide directions to appropriate websites for video demonstrations of autoinjector use. (See 'Information for patients' below.)

-Explain the importance of carrying the epinephrine autoinjector at all times.

-Advise the patient to make sure that family and friends are aware of the risks of anaphylaxis, the causes, and how to administer epinephrine. The correct injection technique is important to avoid unintentional injection into fingers, thumbs, or other body parts [104].

RISK OF RECURRENCE — Patients who have experienced anaphylaxis are at risk for recurrent episodes, unless long-term risk reduction measures are implemented. The risk of recurrence has been estimated in several retrospective studies of different patient populations [22,23,105,106]. In a prospective study of nearly 300 children with anaphylaxis requiring acute medical care (predominantly caused by foods), the annual recurrence rate was 18 percent [107]. Concomitant asthma and the need for epinephrine to treat the initial episode further increased the risk of recurrence. Thus, it is important to equip patients with epinephrine autoinjectors and arrange appropriate referrals in a timely manner after the initial event.

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Anaphylaxis".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Anaphylaxis (The Basics)" and "Patient education: Epinephrine autoinjectors (The Basics)")

Beyond the Basics topics (see "Patient education: Anaphylaxis symptoms and diagnosis (Beyond the Basics)" and "Patient education: Anaphylaxis treatment and prevention of recurrences (Beyond the Basics)" and "Patient education: Using an epinephrine autoinjector (Beyond the Basics)")

Other sources of accurate patient information accessible through the internet include the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology [108,109].

SUMMARY AND RECOMMENDATIONS

Patients with anaphylaxis should be assessed and treated as rapidly as possible, as respiratory or cardiac arrest and death can occur within minutes. Anaphylaxis appears to be most responsive to treatment in its early phases, before shock has developed, based on the observation that delayed epinephrine injection is associated with fatalities. (See 'Immediate management' above.)

Initial management is summarized in rapid overview tables for adults (table 1) and children (table 2). (See 'Immediate management' above.)

Epinephrine is lifesaving in anaphylaxis. It should be injected as early as possible in the episode, in order to prevent progression of symptoms and signs. There are no absolute contraindications to epinephrine use, and it is the treatment of choice for anaphylaxis of any severity. We recommend epinephrine for patients with apparently mild symptoms and signs (eg, a few hives and mild wheezing) (Grade 1B), as well as for patients with moderate-to-severe symptoms and signs (Grade 1A). (See 'Epinephrine' above.)

The route of epinephrine administration depends upon the presenting symptoms. For patients who are not profoundly hypotensive or in shock or cardiorespiratory arrest, intramuscular (IM) injection into the mid-outer thigh as the initial route of administration is advised, in preference to subcutaneous administration or intravenous (IV) administration (table 3). (See 'Intramuscular epinephrine injection (preferred)' above.)

When an exact dose can be drawn up and administered, 0.01 mg/kg (maximum of 0.5 mg) should be administered in the mid-outer thigh every 5 to 15 minutes or more frequently, if necessary.

When an autoinjector is used, children weighing less than 25 kg should receive the 0.15 mg dose, and those weighing over 25 kg should receive the 0.3 mg dose administered to the outer thigh every 5 to 15 minutes or more frequently, if necessary. Autoinjector use must be carefully considered in infants and children weighing under 7.5 kg. However, the benefits likely outweigh the risk if this is the only source of epinephrine available.

Massive fluid shifts can occur in anaphylaxis, and all patients with orthostasis, hypotension, or incomplete response to epinephrine should receive large volume fluid resuscitation with normal saline. Normotensive patients should receive normal saline to maintain venous access in case their status deteriorates. (See 'Intravenous fluids' above.)

Supplemental oxygen and bronchodilators should be administered to patients with respiratory signs or symptoms. (See 'Initial assessment and management' above.)

IV epinephrine is indicated for patients with profound hypotension or symptoms and signs suggestive of impending shock (dizziness, incontinence of urine or stool) who do not respond to initial IM injections of epinephrine and fluid resuscitation. For these patients, we suggest that epinephrine be administered by continuous slow IV infusion, rather than by intermittent IV bolus (Grade 2C). Slow IV infusion is less likely to cause extreme hypertension or ventricular arrhythmias. Epinephrine infusion should be accompanied by continuous electronic hemodynamic monitoring. Specific guidance for creating the proper epinephrine solutions is provided. (See 'Intravenous epinephrine continuous infusion and indications' above.)

Patients successfully treated for anaphylaxis should be discharged with a personalized, written anaphylaxis emergency action plan, an epinephrine autoinjector, written information about anaphylaxis and its treatment, and a plan for further evaluation by an allergist. (See 'Observation and admission' above and 'Follow-up care' above and 'Information for patients' above.)

Patients should be evaluated further to confirm the cause, as specific avoidance measures are useful in reducing the risk of recurrence. (See 'Risk of recurrence' above.)

ACKNOWLEDGMENTS — The editorial staff at UpToDate acknowledge F Estelle R Simons, MD, FRCPC, and Carlos Camargo, Jr, MD, DrPH, who contributed to earlier versions of this topic review.

REFERENCES

  1. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.
  2. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.
  3. Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.
  4. Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.
  5. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285.
  6. Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.
  7. Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252.
  8. Shen Y, Li L, Grant J, et al. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int 2009; 186:1.
  9. Yilmaz R, Yuksekbas O, Erkol Z, et al. Postmortem findings after anaphylactic reactions to drugs in Turkey. Am J Forensic Med Pathol 2009; 30:346.
  10. Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10:354.
  11. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62:830.
  12. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy 2009; 64:204.
  13. Simons FE. Emergency treatment of anaphylaxis. BMJ 2008; 336:1141.
  14. McLean-Tooke AP, Bethune CA, Fay AC, Spickett GP. Adrenaline in the treatment of anaphylaxis: what is the evidence? BMJ 2003; 327:1332.
  15. Simons FE. Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened? Curr Opin Allergy Clin Immunol 2010; 10:384.
  16. Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol 2005; 5:359.
  17. Brown SG, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004; 21:149.
  18. Simons FE. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 2004; 113:837.
  19. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108:871.
  20. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101:33.
  21. Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003; 112:451.
  22. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol 2015; 115:341.
  23. Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587.
  24. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation 2008; 77:157.
  25. Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. Med J Aust 2006; 185:283.
  26. Muraro A, Roberts G, Clark A, et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy 2007; 62:857.
  27. Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol 2014; 113:599.
  28. Brown SG. The pathophysiology of shock in anaphylaxis. Immunol Allergy Clin North Am 2007; 27:165.
  29. Brown SG. Anaphylaxis: clinical concepts and research priorities. Emerg Med Australas 2006; 18:155.
  30. Geerts BF, van den Bergh L, Stijnen T, et al. Comprehensive review: is it better to use the Trendelenburg position or passive leg raising for the initial treatment of hypovolemia? J Clin Anesth 2012; 24:668.
  31. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.
  32. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; :CD000567.
  33. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.
  34. Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.
  35. Kanwar M, Irvin CB, Frank JJ, et al. Confusion about epinephrine dosing leading to iatrogenic overdose: a life-threatening problem with a potential solution. Ann Emerg Med 2010; 55:341.
  36. Kmietowicz Z. UK trainee doctors are still unsure about how to treat anaphylaxis. BMJ 2015; 350:h171.
  37. Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract 2015; 3:76.
  38. Kawano T, Scheuermeyer FX, Stenstrom R, et al. Epinephrine use in older patients with anaphylaxis: Clinical outcomes and cardiovascular complications. Resuscitation 2017; 112:53.
  39. https://www.fda.gov/drugs/information-drug-class/single-entity-injectable-drug-products (Accessed on June 19, 2020).
  40. US Food & Drug Administration. Important Labeling Changes to Critical Care Medications. https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm562565.htm (Accessed on October 10, 2017).
  41. Halbrich M, Mack DP, Carr S, et al. CSACI position statement: epinephrine auto-injectors and children < 15 kg. Allergy Asthma Clin Immunol 2015; 11:20.
  42. Sicherer SH, Simons FER, SECTION ON ALLERGY AND IMMUNOLOGY. Epinephrine for First-aid Management of Anaphylaxis. Pediatrics 2017; 139.
  43. Song TT, Nelson MR, Chang JH, et al. Adequacy of the epinephrine autoinjector needle length in delivering epinephrine to the intramuscular tissues. Ann Allergy Asthma Immunol 2005; 94:539.
  44. Stecher D, Bulloch B, Sales J, et al. Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly? Pediatrics 2009; 124:65.
  45. Kemp SF, Lockey RF, Simons FE, World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy 2008; 63:1061.
  46. Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. Pediatrics 2008; 121:433.
  47. Brown SG, Stone SF, Fatovich DM, et al. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol 2013; 132:1141.
  48. Ben-Shoshan M, La Vieille S, Eisman H, et al. Anaphylaxis treated in a Canadian pediatric hospital: Incidence, clinical characteristics, triggers, and management. J Allergy Clin Immunol 2013; 132:739.
  49. Korenblat P, Lundie MJ, Dankner RE, Day JH. A retrospective study of epinephrine administration for anaphylaxis: how many doses are needed? Allergy Asthma Proc 1999; 20:383.
  50. Uguz A, Lack G, Pumphrey R, et al. Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign. Clin Exp Allergy 2005; 35:746.
  51. Järvinen KM, Sicherer SH, Sampson HA, Nowak-Wegrzyn A. Use of multiple doses of epinephrine in food-induced anaphylaxis in children. J Allergy Clin Immunol 2008; 122:133.
  52. Oren E, Banerji A, Clark S, Camargo CA Jr. Food-induced anaphylaxis and repeated epinephrine treatments. Ann Allergy Asthma Immunol 2007; 99:429.
  53. Kelso JM. A second dose of epinephrine for anaphylaxis: how often needed and how to carry. J Allergy Clin Immunol 2006; 117:464.
  54. Manivannan V, Campbell RL, Bellolio MF, et al. Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009; 103:395.
  55. Rudders SA, Banerji A, Corel B, et al. Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics 2010; 125:e711.
  56. Campbell RL, Bashore CJ, Lee S, et al. Predictors of Repeat Epinephrine Administration for Emergency Department Patients with Anaphylaxis. J Allergy Clin Immunol Pract 2015; 3:576.
  57. Wheeler DW, Carter JJ, Murray LJ, et al. The effect of drug concentration expression on epinephrine dosing errors: a randomized trial. Ann Intern Med 2008; 148:11.
  58. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S829.
  59. Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132:S501.
  60. Le A, Patel S. Extravasation of Noncytotoxic Drugs: A Review of the Literature. Ann Pharmacother 2014; 48:870.
  61. Reynolds PM, MacLaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy 2014; 34:617.
  62. Vadas P, Perelman B. Effect of epinephrine on platelet-activating factor-stimulated human vascular smooth muscle cells. J Allergy Clin Immunol 2012; 129:1329.
  63. Kounis NG. Coronary hypersensitivity disorder: the Kounis syndrome. Clin Ther 2013; 35:563.
  64. Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.
  65. Ridella M, Bagdure S, Nugent K, Cevik C. Kounis syndrome following beta-lactam antibiotic use: review of literature. Inflamm Allergy Drug Targets 2009; 8:11.
  66. Biteker M, Duran NE, Biteker FS, et al. Allergic myocardial infarction in childhood: Kounis syndrome. Eur J Pediatr 2010; 169:27.
  67. Anchor J, Settipane RA. Appropriate use of epinephrine in anaphylaxis. Am J Emerg Med 2004; 22:488.
  68. Fleming JT, Clark S, Camargo CA Jr, Rudders SA. Early treatment of food-induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization. J Allergy Clin Immunol Pract 2015; 3:57.
  69. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.
  70. Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 2009; 123:493.
  71. Nassiri M, Babina M, Dölle S, et al. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol 2015; 135:491.
  72. White JL, Greger KC, Lee S, et al. Patients Taking β-Blockers Do Not Require Increased Doses of Epinephrine for Anaphylaxis. J Allergy Clin Immunol Pract 2018; 6:1553.
  73. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22:272.
  74. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.
  75. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128:1139.
  76. Ellis BC, Brown SG. Parenteral antihistamines cause hypotension in anaphylaxis. Emerg Med Australas 2013; 25:92.
  77. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36:462.
  78. Nurmatov UB, Rhatigan E, Simons FE, Sheikh A. H2-antihistamines for the treatment of anaphylaxis with and without shock: a systematic review. Ann Allergy Asthma Immunol 2014; 112:126.
  79. Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012; :CD008596.
  80. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082.
  81. Francuzik W, Dölle-Bierke S, Knop M, et al. Refractory Anaphylaxis: Data From the European Anaphylaxis Registry. Front Immunol 2019; 10:2482.
  82. Dewachter P, Mouton-Faivre C, Emala CW. Anaphylaxis and anesthesia: controversies and new insights. Anesthesiology 2009; 111:1141.
  83. Puttgen HA, Mirski MA. The level of evidence 5 blues: investigating medicine when experience trumps equipoise. Crit Care Med 2013; 41:359.
  84. Hosseinian L, Weiner M, Levin MA, Fischer GW. Methylene Blue: Magic Bullet for Vasoplegia? Anesth Analg 2016; 122:194.
  85. Bauer CS, Vadas P, Kelly KJ. Methylene blue for the treatment of refractory anaphylaxis without hypotension. Am J Emerg Med 2013; 31:264.e3.
  86. Zheng F, Barthel G, Collange O, et al. Methylene blue and epinephrine: a synergetic association for anaphylactic shock treatment. Crit Care Med 2013; 41:195.
  87. Lafforgue E, Sleth JC, Pluskwa F, Saizy C. [Successful extracorporeal resuscitation of a probable perioperative anaphylactic shock due to atracurium]. Ann Fr Anesth Reanim 2005; 24:551.
  88. Allen SJ, Gallagher A, Paxton LD. Anaphylaxis to rocuronium. Anaesthesia 2000; 55:1223.
  89. Grunau BE, Li J, Yi TW, et al. Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis. Ann Emerg Med 2014; 63:736.
  90. Forrest-Hay A, Taylor C, Tolchard S. Biphasic anaphylaxis in a UK emergency department. Presented at Open Paper Presentations of the 2003 Scientific Symposium of the Resuscitation Council of the United Kingdom (Abstract).
  91. Pourmand A, Robinson C, Syed W, Mazer-Amirshahi M. Biphasic anaphylaxis: A review of the literature and implications for emergency management. Am J Emerg Med 2018; 36:1480.
  92. Kemp SF. The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms? Curr Allergy Asthma Rep 2008; 8:45.
  93. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115:S483.
  94. Soar J, Deakin CD, Nolan JP, et al. European Resuscitation Council guidelines for resuscitation 2005. Section 7. Cardiac arrest in special circumstances. Resuscitation 2005; 67 Suppl 1:S135.
  95. Manivannan V, Hess EP, Bellamkonda VR, et al. A multifaceted intervention for patients with anaphylaxis increases epinephrine use in adult emergency department. J Allergy Clin Immunol Pract 2014; 2:294.
  96. Rohacek M, Edenhofer H, Bircher A, Bingisser R. Biphasic anaphylactic reactions: occurrence and mortality. Allergy 2014; 69:791.
  97. Lee S, Bellolio MF, Hess EP, et al. Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis. J Allergy Clin Immunol Pract 2015; 3:408.
  98. Lee S, Peterson A, Lohse CM, et al. Further Evaluation of Factors That May Predict Biphasic Reactions in Emergency Department Anaphylaxis Patients. J Allergy Clin Immunol Pract 2017; 5:1295.
  99. Lee J, Rodio B, Lavelle J, et al. Improving Anaphylaxis Care: The Impact of a Clinical Pathway. Pediatrics 2018; 141.
  100. Simons FE, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009; 124:301.
  101. Campbell RL, Park MA, Kueber MA Jr, et al. Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis. J Allergy Clin Immunol Pract 2015; 3:88.
  102. The Be S.A.F.E. campaign is discussed on the website of the American College of Allergy, Asthma and Immunology. http://www.acaai.org/allergist/allergies/Anaphylaxis/Pages/safe-awareness-anaphylaxis.aspx (Accessed on May 09, 2014).
  103. Lieberman P, Decker W, Camargo CA Jr, et al. SAFE: a multidisciplinary approach to anaphylaxis education in the emergency department. Ann Allergy Asthma Immunol 2007; 98:519.
  104. Simons FE, Edwards ES, Read EJ Jr, et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010; 125:419.
  105. Mullins RJ. Anaphylaxis: risk factors for recurrence. Clin Exp Allergy 2003; 33:1033.
  106. Lee S, Bashore C, Lohse CM, et al. Rate of recurrent anaphylaxis and associated risk factors among Olmsted County, Minnesota, residents: A population-based study. Ann Allergy Asthma Immunol 2016; 117:655.
  107. O'Keefe A, Clarke A, St Pierre Y, et al. The Risk of Recurrent Anaphylaxis. J Pediatr 2017; 180:217.
  108. The American College of Allergy, Asthma and Immunology. www.acaai.org (Accessed on August 13, 2009).
  109. The American Academy of Allergy, Asthma and Immunology. www.aaaai.org (Accessed on August 13, 2009).
Topic 392 Version 58.0

References

1 : Lessons for management of anaphylaxis from a study of fatal reactions.

2 : Fatal and near-fatal anaphylactic reactions to food in children and adolescents.

3 : Fatalities due to anaphylactic reactions to foods.

4 : Further fatalities caused by anaphylactic reactions to food, 2001-2006.

5 : Anaphylaxis: can we tell who is at risk of a fatal reaction?

6 : Further fatal allergic reactions to food in the United Kingdom, 1999-2006.

7 : Fatal anaphylaxis: postmortem findings and associated comorbid diseases.

8 : Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006.

9 : Postmortem findings after anaphylactic reactions to drugs in Turkey.

10 : Epinephrine and its use in anaphylaxis: current issues.

11 : H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review.

12 : Adrenaline for the treatment of anaphylaxis: cochrane systematic review.

13 : Emergency treatment of anaphylaxis.

14 : Adrenaline in the treatment of anaphylaxis: what is the evidence?

15 : Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened?

16 : Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis.

17 : Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation.

18 : First-aid treatment of anaphylaxis to food: focus on epinephrine.

19 : Epinephrine absorption in adults: intramuscular versus subcutaneous injection.

20 : Epinephrine absorption in children with a history of anaphylaxis.

21 : Fatal posture in anaphylactic shock.

22 : Anaphylaxis--a practice parameter update 2015.

23 : World Allergy Organization anaphylaxis guidelines: summary.

24 : Emergency treatment of anaphylactic reactions--guidelines for healthcare providers.

25 : Anaphylaxis: diagnosis and management.

26 : The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology.

27 : Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.

28 : The pathophysiology of shock in anaphylaxis.

29 : Anaphylaxis: clinical concepts and research priorities.

30 : Comprehensive review: is it better to use the Trendelenburg position or passive leg raising for the initial treatment of hypovolemia?

31 : Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

32 : Colloids versus crystalloids for fluid resuscitation in critically ill patients.

33 : Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

34 : Anaphylaxis, killer allergy: long-term management in the community.

35 : Confusion about epinephrine dosing leading to iatrogenic overdose: a life-threatening problem with a potential solution.

36 : UK trainee doctors are still unsure about how to treat anaphylaxis.

37 : Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine.

38 : Epinephrine use in older patients with anaphylaxis: Clinical outcomes and cardiovascular complications.

39 : Epinephrine use in older patients with anaphylaxis: Clinical outcomes and cardiovascular complications.

40 : Epinephrine use in older patients with anaphylaxis: Clinical outcomes and cardiovascular complications.

41 : CSACI position statement: epinephrine auto-injectors and children < 15 kg.

42 : Epinephrine for First-aid Management of Anaphylaxis.

43 : Adequacy of the epinephrine autoinjector needle length in delivering epinephrine to the intramuscular tissues.

44 : Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly?

45 : Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization.

46 : Preparing for pediatric emergencies: drugs to consider.

47 : Anaphylaxis: clinical patterns, mediator release, and severity.

48 : Anaphylaxis treated in a Canadian pediatric hospital: Incidence, clinical characteristics, triggers, and management.

49 : A retrospective study of epinephrine administration for anaphylaxis: how many doses are needed?

50 : Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign.

51 : Use of multiple doses of epinephrine in food-induced anaphylaxis in children.

52 : Food-induced anaphylaxis and repeated epinephrine treatments.

53 : A second dose of epinephrine for anaphylaxis: how often needed and how to carry.

54 : Factors associated with repeated use of epinephrine for the treatment of anaphylaxis.

55 : Multicenter study of repeat epinephrine treatments for food-related anaphylaxis.

56 : Predictors of Repeat Epinephrine Administration for Emergency Department Patients with Anaphylaxis.

57 : The effect of drug concentration expression on epinephrine dosing errors: a randomized trial.

58 : Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

59 : Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

60 : Extravasation of Noncytotoxic Drugs: A Review of the Literature.

61 : Management of extravasation injuries: a focused evaluation of noncytotoxic medications.

62 : Effect of epinephrine on platelet-activating factor-stimulated human vascular smooth muscle cells.

63 : Coronary hypersensitivity disorder: the Kounis syndrome.

64 : Allergy and the cardiovascular system.

65 : Kounis syndrome following beta-lactam antibiotic use: review of literature.

66 : Allergic myocardial infarction in childhood: Kounis syndrome.

67 : Appropriate use of epinephrine in anaphylaxis.

68 : Early treatment of food-induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization.

69 : Allergen immunotherapy: a practice parameter third update.

70 : Incidence and characteristics of biphasic reactions after allergen immunotherapy.

71 : Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming.

72 : Patients Takingβ-Blockers Do Not Require Increased Doses of Epinephrine for Anaphylaxis.

73 : Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers.

74 : The diagnosis and management of anaphylaxis practice parameter: 2010 update.

75 : Histamine and H1-antihistamines: celebrating a century of progress.

76 : Parenteral antihistamines cause hypotension in anaphylaxis.

77 : Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists.

78 : H2-antihistamines for the treatment of anaphylaxis with and without shock: a systematic review.

79 : Histamine H2-receptor antagonists for urticaria.

80 : Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.

81 : Refractory Anaphylaxis: Data From the European Anaphylaxis Registry.

82 : Anaphylaxis and anesthesia: controversies and new insights.

83 : The level of evidence 5 blues: investigating medicine when experience trumps equipoise.

84 : Methylene Blue: Magic Bullet for Vasoplegia?

85 : Methylene blue for the treatment of refractory anaphylaxis without hypotension.

86 : Methylene blue and epinephrine: a synergetic association for anaphylactic shock treatment.

87 : [Successful extracorporeal resuscitation of a probable perioperative anaphylactic shock due to atracurium].

88 : Anaphylaxis to rocuronium.

89 : Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis.

90 : Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis.

91 : Biphasic anaphylaxis: A review of the literature and implications for emergency management.

92 : The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms?

93 : The diagnosis and management of anaphylaxis: an updated practice parameter.

94 : European Resuscitation Council guidelines for resuscitation 2005. Section 7. Cardiac arrest in special circumstances.

95 : A multifaceted intervention for patients with anaphylaxis increases epinephrine use in adult emergency department.

96 : Biphasic anaphylactic reactions: occurrence and mortality.

97 : Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis.

98 : Further Evaluation of Factors That May Predict Biphasic Reactions in Emergency Department Anaphylaxis Patients.

99 : Improving Anaphylaxis Care: The Impact of a Clinical Pathway.

100 : Anaphylaxis in the community: learning from the survivors.

101 : Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis.

102 : Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis.

103 : SAFE: a multidisciplinary approach to anaphylaxis education in the emergency department.

104 : Voluntarily reported unintentional injections from epinephrine auto-injectors.

105 : Anaphylaxis: risk factors for recurrence.

106 : Rate of recurrent anaphylaxis and associated risk factors among Olmsted County, Minnesota, residents: A population-based study.

107 : The Risk of Recurrent Anaphylaxis.